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Background: Very little is known about the genetics of cystic fibrosis (CF) from the Indian subcontinent. The aims of the study were to
identify the mutations and study the relation of genotype with phenotype in Indian children with CF.
Methods: A total of 100 patients with CF were screened for mutations in the CFTR gene. These included c.1521_1523delCTT (p.F508del)
and c.3849+10 kb CNT mutations followed by single strand conformation polymorphism/heteroduplex analysis for mutations in 19 out of 27
exons of the CFTR gene.
Results: At least one mutation was identified in 40 patients. The most common mutation identified was p.F508del; 20 patients were
homozygous and 13 heterozygous. In addition, c.3849+10 kb CNT, c.1161delC, and p.S549N were identified in two patients each and p.
R352Q, p.R1158X and p.R75Q were identified in one patient each. Three novel mutations, viz. c.1002-7_1002-5delTTT, p.G149X and p.
L183I were also identified. Majority of patients who were p.F508del positive originated from Pakistan and north-western states of India. The
phenotypes of all patients were classical. Genotype–phenotype correlation revealed that p.F508del positive patients had a more severe
disease, manifesting at an earlier age.
Conclusions: A strategy for mutation screening for CF in India must involve testing for p.F508del followed by c.1161delC, c.3849+10 kb
CNT and p.S549N. There is a need for large multicentric studies using more sensitive techniques for the identification of mutations in Indian
CF patients.
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1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.06.0047. CF is the most common fatal genetic disorder among
Caucasians, with an incidence of approximately 1 in 2000 to
4000 births, and is relatively less common amongAfricans and
Asians [1]. More than 1300 mutations in the CFTR gene have
been reported to the Cystic Fibrosis Genetic Analysis
Consortium (CFGAC) (http://www.genet.sickkids.on.ca).
CF has been reported from India since the 1960s, but the
precise prevalence rate is still unknown [2–4]. The estimated
prevalence of CF among Indians living in UK and USA is 1
in 10,000 to 1 in 12,000 and 1 in 40,000 respectively [5–7].
The prevalence of CF in a north Indian population was
estimated to be 1 in 43,321 to 1 in 100,323 by screening 955
cord blood samples for the presence of p.F508del mutationed by Elsevier B.V. All rights reserved.
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Indian CF children indicate that p.F508del is the most
common mutation, accounting for about 19–40% of the
mutations [9–12]. Identification of the mutations is of great
importance for further evaluation, patient counselling and
prenatal diagnosis [13]. In this study, we aimed to identify
the mutation spectrum in Indian patients with CF, which
would help us in forming a strategy for DNA-based diag-
nosis, and to compare the genotypes with phenotypes.
2. Materials and methods
The present studywas carried out as a descriptive pilot study
on 100 patients at the Genetics Unit of Department of
Paediatrics at All India Institute of Medical Sciences, New
Delhi, India over a period of 5 years from 1999 to 2004. The
study population included patients attending the paediatric
outpatient clinics (paediatric chest and genetics clinics) and
those who were admitted in the paediatric medicine or surgery
wards with a suspected diagnosis of CF. Patients with sweat
chloride values of N60 mEq/L on two or more occasions were
included in the study. All children were scored on a scale of 5 to
25 based on their nutritional status, physical activity, pulmonary
and radiological findings [14]. A composite score (CF score)
was calculated by summing up all four scores; a score of N80
suggested mild disease and b40 an advanced disease.
Approximately 5 mL of blood sample in EDTA was
collected from each patient and DNA was extracted by
standard phenol–chloroform (for stored samples) [15] or by
salting-out (for fresh samples) method [16].
2.1. Mutation analysis
Initially, all patients were tested for p.F508del and c.3849+
10 kb CNT mutations. The samples which were negative for
these two mutations were analysed by single strand confor-
mation polymorphism/heteroduplex analysis (SSCP/HA) of
19 out of 27 exons of theCFTR gene, in which mutations were
commonly seen (exons 3, 4, 7, 10, 11, 12, 13A, 13B, 19, 20, 21
and 2, 5, 9, 14a, 14b, 16, 17a, 17b and 23) [11]. The samples
that showed a shift in the band pattern were sequenced. For p.
F508del, a 50 base pair region flanking this deletion was
amplified by PCR using a previously published protocol and
run on 10% PAGE [17]. The analysis of c.3849+10 kb CNT
was done by amplifying 437 bp region in the intron 19 and
restriction withHph I [18]. PCR for SSCP/HAwas carried out
in 25 μL volumes. For fragments which were large, restriction
digestion was carried out.
3. Results
3.1. Demographic profile of the patients
The origin of patients could be traced to almost all states
in north India. The maximum number (23) of patients had
their origin from the state of Uttar Pradesh (Fig. 1). The othercommon place of origin was the neighbouring country of
Pakistan with history of migration to India (16), followed by
the states of West Bengal (10) and Delhi (8). The place of
origin of the father and mother was different for five patients.
The patients were predominantly male (62 males and 38
females). Consanguinity was present in 13 families. History
of a confirmed case of CF in the family was present in two
cases. Clinical history, highly suggestive of CF in a previous
child but not proven, was present in 26 patients.
The mean (±SD) and median (IQR) age at diagnosis were
52.7±60.2 and 30 (8.0–72.0) months respectively although
more than half of the patients (54) had developed at least one
symptom suggestive of CF by three months. One patient was
diagnosed in the first week after birth. The oldest age at
diagnosis was 28 years. The mean age at onset of symptoms
was 10.7months and themedian age at onset of symptomswas
2.8 months. Thirty-four patients were diagnosed within the
first year of life and 96 patients were diagnosed by 16 years.
3.2. Clinical profile
3.2.1. Symptoms and CF score
A total of 98 patients had recurrent or persistent
pneumonia at the time of presentation. Malabsorption was
present in 85/97 (88%) and failure to thrive (FTT) in 95/98
(97%) of patients. Hepatomegaly (N2 cm) was present in 18/
91 (20%). The mean CF score calculated was 49±15.8,
indicating advanced disease at the time of diagnosis.
Eighteen (20%) patients had evidence of advanced disease
with a CF score of b40. There were 42 patients with a score
of 40–60 and 32 patients with a score of N60. Clubbing was
present in 66/97 (68%) of patients.
3.2.2. Anthropometry and nutritional status
Physical examination revealed malnutrition in 72/82
(88%) of patients (Indian Academy of Paediatrics classifi-
cation) in whom detailed anthropometry was available.
Grade I, II, III and IV malnutrition was seen in 18.5, 25.6,
24.4 and 19.5% patients respectively.
3.3. Laboratory findings
The mean sweat chloride was 97.6 mEq/L in 93 patients
tested. Sweat chloride could not be analysed in a few patients
due to poor sweat weight or advanced disease state. Pseu-
domonas spp was cultured from respiratory secretions of 45/
97 (46%) patients and Staphylococcus spp in 11/96 (11%).
Other laboratory tests such as blood counts, liver function
tests, chest X-rays, CT chest, ultrasound of abdomen and fat
malabsorption studies were performed on individualised
basis at the time of enrolment and during follow up.
3.4. Mutation analysis
Testing for p.F508del, c.3849+10 kb CNT and SSCP/HA
of 19 exons of the CFTR gene in the 100 CF patients (i.e. in
Fig. 1. Map of India showing the area of origin of patients.
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patients (66 chromosomes) (Table 1). Out of these 22 were
homozygous for a specific mutation. The most common
mutation was p.F508del, identified either in homozygous or
heterozygous condition in 33 (33%) patients and 53 (26.5%)
of chromosomes. Three other mutations, c.3849+10 kb
CNT, c.1161delC and p.S549N were seen in two patients
each. Frequency of other mutations did not exceed 1%.
3.4.1. SSCP/HA
SSCP/HA identified at least one mutation in exons 3, 4, 7,
11 and 19 viz. p.R75Q in exon 3, p.G149X in exon 4,c.1161delC, p.R352Q and c.1002-7_1002-5delTTT in exon
7, p.S549N in exon 11 and p.R1158X in exon 19. A mutation
(p.L183I) was detected in exon 5.
3.4.2. Novel mutations identified
Three mutations (c.1002-7_1002-5delTTT, p.L183I, p.
G149X) unpublished so far (Table 2) were detected in one
patient each. While c.1002-7 to 1002-5delTTT was detected
in homozygous state, p.L183I and p.G149X were detected in
heterozygous state. Reports of these mutations have been
submitted to the Cystic Fibrosis Genetic Analysis
Consortium.
Table 1
Genotype of the 100 patients with cystic fibrosis
Mutation Number of patients (n=100)
p.[F508del]+[F508del] 20
p.[F508del]+[?] 9
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On comparing patients with p.F508del (both homozygous
and heterozygous) and others patients (both mutation
positive and negative), there was a significant difference
observed in the age at onset (2.3±2.6 vs. 14.5±22.4 months;
p= 0.000), age at diagnosis (40.9 ± 76.9 vs. 58.2 ±
50.4 months; p=0.006) and CF score (40.8±13.8 vs. 52.1±
15.5; p=0.02), all being lower in p.F508del positive patients.
The mean sweat chloride level (107.7±20.5 vs. 93.5±
30.6 mEq/L; p=0.013) was higher in p.F508del positive
group.
The new mutations showed a clinical profile similar to
classical CF. Severe clinical phenotype was seen in a patient
with p.G149Xmutation and low CF score, whereas milder CF
phenotype was seen in the two patients with c.1002-7_1002-
5delTTT and p.L183I. The patient with c.1002-7_1002-
5delTTT mutation had predominantly gastrointestinal symp-
toms and lower respiratory tract infections were not present.
It was interesting to note that the majority of patients with
p.F508del originated from Pakistan. Out of 33 patients who
had p.F508del on one or both chromosomes, 17 patients
originated from Pakistan and neighbouring states of India
namely Jammu and Kashmir, Punjab and Gujarat. Follow-up
was available in 80 patients. Nine patients had expiredTable 2
New mutations identified in patients with cystic fibrosis
Mutation 1 Mutation 2
Exon/intron Exon 4 Intron 6b
Mutation p.G149X (c.577GNT) c.1002-7_1002
Resulting change Stop codon at 149 Deletion of 3 b
Genotype of the patient p.[F508del]+[G149X] c.[1002-7_100
Gender Male Female
Age at diagnosis (months) 2 54
LRTI a Yes No
Malabsorption Yes Yes
CF score 30 80
Sweat chloride (mEq/L) 98 b 200, 47
a LRTI— Lower respiratory tract infections.
b Sweat chloride was done only once.during follow-up. Of these six were p.F508del homozy-
gotes, one was compound heterozygous for p.F508del with
p.R1158X and another was homozygous for c.1161delC.




CF was not confined to any particular geographic area of
India. Consanguinity was present in 13% of the patients.
This is similar to earlier reports from India [19,20] but less
than that reported (50%) by Spencer et al. [7] from Indian
subcontinent patients in UK. Out of the 13 patients born to
consanguineous parents, eight were homozygous (7 for p.
F508del and 1 for c.1161delC) and one was heterozygous
(for c.1161delC); suggesting consanguinity results in a
higher risk of homozygous CF mutations in India. Male
preponderance observed in this study (male: female ratio of
1.6:1) may be due to the preferential treatment given to male
children in the society.
4.2. Clinical profile
The mean age at diagnosis (52.7 months) was much higher
than themean age at diagnosis of CF children inUSA,which is
6 months. The mean age at onset of symptoms was 10.7±
19.5 months and the median was 2.8 (1–9) months in this
study. A wide gap between onset of symptoms and diagnosis
highlights the need for a better awareness programme about
CF in India. The clinical features recorded in this study were
consistent with the classical CF phenotypes described
[9,14,21,22]. The clinical scores of patients (mean 49±15.8)
suggest an already advanced disease at the time of diagnosis,
probably related to delayed diagnosis.
4.3. Laboratory investigations
The mean sweat chloride level (97.6±28.7 mEq/L) was
similar to earlier reports from India [19,23]. The frequencyMutation 3
Exon 5
-5delTTT p.L183I (c.679CNA)
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antibiotic resistance is higher in Indian children with CF
[23].
4.4. Mutation profile
Out of 200 chromosomes tested, mutations could be
identified in 66. In a previous study of 24 patients from our
centre with similar methodology as in the present study, at
least one mutation could be identified in 75% of patients
[11]. A review of worldwide analysis of CFTR mutations
[24] has shown that the rate of mutation detection varies
from a maximum of 100% in Belgium to a minimum of
33.3% in Venezuela. The mutation detection rate was higher
in patients originating from Pakistan and neighboring states
of India. WHO has estimated the mutation detection rate in
Indian CF patients to be about 50–59% [25]. In a subgroup
of patients studied by McCormick et al. in UK, with data for
27 common mutations, at least one mutation could be iden-
tified in 9 out of 12 Indian patients, 32 out of 52 Pakistani
patients and 3 out of 6 Bangladeshi patients [26].
In a compilation of data on mutations in Asian patients in
the US, mutations were identified in 50% of patients [6]. In
another study mutations were identified in nearly 86% (22
out of 26 patients) of patients with Pakistani origin, of which
15 were homozygous [27].
The low mutation detection rate in our study could be due
to low sensitivity of SSCP under the conditions we have
used. Secondly, although the exons selected carried majority
of the mutations that have been reported, the mutations in our
CF patients could be residing in other exons or introns of the
gene, which were not screened.
4.4.1. Novel mutations
c.1002-7_1002-5delTTT results in the deletion of 3
thymidine at the acceptor site of intron 6b/ exon 7 boundary.
This mutation in homozygous condition was seen in a 54-
months old girl who originated from Punjab and was
admitted in the paediatric ward. She had predominantly
gastrointestinal symptoms.
p.G149X is a nonsense mutation resulting from the sub-
stitution of guanine by thymidine at the nucleotide position
577. This transversion changes the codon 149 from GAA to
UAA resulting in replacement of the amino acid 149 from
glycine to stop codon. This is an amino acid present in the
hydrophobic transmembrane domain of the CFTR. This
mutation was identified in a in a boy at two months of age.
He was compound heterozygous for p.F508del with p.G149X
and had meconium ileus, lower respiratory tract infections
(LRTI) and severe FTT.
p.L183I is a substitution of cytosine by adenosine at the
nucleotide position 679, which changes the amino acid 183
to isoleucine from leucine. This amino acid is also a part of
hydrophobic transmembrane domain. This was a 7-year old
girl with LRTI, sinusitis, malabsorption and FTT. Her other
mutation has not been not identified yet.4.5. Genotype–phenotype correlation
The phenotypes of the patients in the present study were
similar to that described in literature [21,22]. Other studies
have not found a significant difference in the phenotype of
patients with different genotypes except for few mutations
such as c.3849+10 kb CNT [28]. This may be due to early
diagnosis and optimal treatment in the Western countries.
Most of the children in this study were not getting
appropriate enzyme replacement at the time of diagnosis
and even after diagnosis, which caused severe malnutrition
and a severe disease in them.
This study has shown that there is a considerable dif-
ference in the mutation spectrum of CF patients originating
from Pakistan and the neighbouring states of India. Half of
the CF patients from this region are either homozygous or
heterozygous for p.F508del while only one in six CF patients
from the rest of India is p.F508del positive.
Since p.F508del is the commonest mutation in our CF
population, any national strategy for mutation screening in
CF must start with testing for p.F508del. Simple PCR-based
methods are already in wide use for the identification of this
mutation. This should be followed by screening for the other
three common mutations, p.S549N, c.3849+10 kb CNT and
c.1161delC identified in this study. PCR-based identifica-
tion of common mutations is available [18,29] and new
methods are being continually developed. When the
mutations are not identified in the index child, prenatal
diagnosis may be performed using dinucleotide repeat
markers, which are generally informative [30,31]. Despite
some limitations, the present study has managed to answer
some of the questions related to CF mutations in Indian CF
patients.
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